ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens. These findings were reported at the American Society of Hematology [...]

For women just diagnosed with breast cancer, one of the important decisions confronting them is whether to have a lumpectomy or mastectomy. A diagnosis of breast cancer will affect one in every eight women in the United States, according to the American Cancer Society, causing them to have to decide quickly about treatment.

Breast cancer therapy that’s customized for each patient’s personal genetic makeup is one step closer to reality, thanks to a new use for crime-lab technology pioneered at Roswell Park Cancer Institute (RPCI). A team led by Petr Starostik, MD, chief of RPCI’s Clinical Molecular Diagnostics lab, is using CSI-type methods to multiply the reliability of [...]

Chronic periodontitis, a form of gum disease, is an independent risk factor for head and neck squamous cell carcinoma. This suggests the need for increased efforts to prevent and treat periodontitis as a possible means to reduce the risk of this form of cancer.

The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein a cancer vaccine that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.